Synaptogenix to Present at Upcoming Scientific Industry Conferences
NEW YORK, Feb. 25, 2021 -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will attend two upcoming scientific industry conferences.
On Thursday, February 25th, Dr. Daniel Alkon M.D., President and Chief Scientific Officer, will present a virtual poster at the 9th Annual Neurodegenerative Drug Development Summit. The virtual posters begin at 5pm ET and the Synaptogenix presentation can be accessed via the following link.
Click Here: Neurodegenerative Drug Development Summit
Also, on Sunday, March 14th at 10am ET, Dr. Daniel Alkon M.D. will present at the 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2021). The presentation is entitled: "Evidence for Generality of a Neuro-Regenerative Therapeutic Strategy with Bryostatin." "The pre-clinical and clinical findings discussed will include data citing a significant improvement, 4.8 points above baseline Severe Impairment Battery scores, in pre-specified cohorts of advanced Alzheimer's disease ("AD") patients in a recent pilot Phase 2 clinical trial that persisted at least 30 days after the last Bryostatin-1 dose was administered," stated Dr. Alkon.
Additional information can be found at: AD/PD 2021
Dr. Alan Tuchman M.D., Chief Executive Officer, stated, "We are excited to continue talking about data from our pilot Phase 2 AD studies and look forward to sharing additional updates on our ongoing Phase 2 trial under enrollment at this time."
About Synaptogenix, Inc.
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel neuro-regenerative drug therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease, and preclinical studies for rare diseases such as Fragile X syndrome, Niemann-Pick Type C disease, and Rett syndrome, as well as multiple sclerosis, autistic spectrum disorder, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,600 people in cancer and AD studies, thus creating a large safety data base that will further inform clinical trial designs.
Additional information about Synaptogenix, Inc. may be found on its website: www.synaptogen.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 study and further studies, and continued development of use of Bryostatin-1 for AD and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.
Investors and Media
Chief Financial Officer
SOURCE Synaptogenix, Inc.